At a glance
- Hers tirzepatide in 2026 means brand Zepbound only. Priced at $1,899/month for the pen.
- Add Hers membership: $39 first month, $149/month after. All-in year-one runs ~$24,527.
- Same molecule on LillyDirect self-pay vials: $299 (2.5 mg), $399 (5 mg), $449 (7.5-15 mg).
- 503A compounded tirzepatide via licensed telehealth still exists in 2026 from about $139/month.
- SURMOUNT-5 (Aronne 2025, PMID 40353578): tirzepatide beat semaglutide 20.2% vs 13.7% at 72 weeks.
Hers charges $1,899 per month for tirzepatide in mid-2026. That is brand-name Zepbound in an auto-injector pen, dispensed under a $39 first-month, $149-per-month membership. The compounded tirzepatide Hims sold in 2024 is no longer on the menu, and the current path buys the exact same molecule you can get from LillyDirect for roughly a fifth of the price.
This guide prices Hers end to end for 2026: what you actually pay including membership, what changed after the FDA and the courts ended the tirzepatide compounding window, and which legal paths deliver the same molecule for less. The comparison is not a knock on Hers as a clinical program. It is a straight cost accounting for a buyer typing "hers tirzepatide cost" into a search bar and expecting a real number back.
What Hers actually sells in 2026
Hers is the women-focused arm of Hims & Hers Health. For most of 2024 the platform sold compounded tirzepatide through a partnered 503B outsourcing facility under the FDA shortage-era enforcement discretion. That window closed. Judge Mark Pittman upheld the FDA's determination that tirzepatide was no longer in shortage, 503B compounding of tirzepatide stopped on March 19, 2025, and Eli Lilly filed suit in April 2025 against Mochi, Fella, Henry Meds, and Willow for continuing to market copies. Hims & Hers pivoted its GLP-1 catalog: compounded semaglutide remains through licensed 503A prescribers for eligible patients, but the tirzepatide path is now brand Zepbound, dispensed through the Lilly channel and delivered under the Hers telehealth wrap.
Concretely, the product on the Hers weight-loss page today is Zepbound in the KwikPen auto-injector, prescribed by a Hers-network licensed clinician after an online intake. It is the identical molecule and pen a retail pharmacy dispenses, priced through the platform rather than a pharmacy counter.
Note: The Hers compounded semaglutide plan still exists and starts near $199 for the first month, with monthly pricing that varies by dose and plan length. That is a different drug from tirzepatide and a different affiliate market. This guide is scoped to the tirzepatide question specifically.
The all-in monthly cost, not just the sticker
Cost calculators that quote "$1,899/mo" for Hers Zepbound leave out the recurring membership. Cost calculators that quote "$149/mo" for Hers weight-loss membership leave out the drug. Both together is the number that hits your card.
| Line item | First month | Steady state |
|---|---|---|
| Zepbound auto-injector pen through Hers | $1,899 | $1,899 |
| Hers weight-loss membership | $39 | $149 |
| Total per month | $1,938 | $2,048 |
| Total, year one | - | ~$24,527 |
That is a real number. At today's Hers Zepbound pricing, a year-one buyer sends the platform roughly the price of a used car. The drug itself is not the driver of the surcharge relative to alternatives: Lilly sells the same pen through the branded pharmacy network at a comparable list price. What Hers layers on is the telehealth wrapper (clinician access, refills, shipping, program support) and the membership.
None of that is inherently unreasonable. It is unreasonable relative to what the same molecule costs on paths Hers does not run.
The comparison Hers does not show you
Zepbound and its diabetes twin Mounjaro are both tirzepatide, the same molecule at the same doses (see our tirzepatide dosage chart). The molecule that enters your bloodstream is identical whether you buy it through Hers, through LillyDirect, or through a licensed 503A compounding path. The differences are label, format (vial versus pen), and how much of the fee stack goes to a telehealth intermediary.
| Path | Format | 2.5 mg | 5 mg | 7.5-15 mg | The catch |
|---|---|---|---|---|---|
| Hers (brand Zepbound) | Pen | $1,899 | $1,899 | $1,899 | Plus $149/mo membership |
| LillyDirect Self-Pay | Vial | $299 | $399 | $449 flat | 45-day refill window on 7.5+ tier |
| Bodybuilding Health+ (503A compounded) | Vial | from $139 | from $139 | varies | Patient-specific Rx; not FDA-approved |
| Gala Health (503A compounded microdose) | Vial | from $149 | from $149 | varies | Microdose tier is not commercial equivalent |
| TelosRx (503A compounded microdose) | Vial or oral | from $49 | from $49 | varies | Microdose tier; 12-month plan pricing |
| Retail cash pen | Pen | ~$1,086 | ~$1,086 | ~$1,270 | List price at CVS/Walgreens |
Two rows to read twice. LillyDirect single-dose vials at $299 to $449 deliver the same tirzepatide as Hers's pen for about a fifth of the sticker. And a licensed 503A compounding path through a legitimate US telehealth partner starts under $150 per month. Our cheapest Zepbound path guide prices these in more detail, and /glp-1/cheapest is the site's live monthly-price hub.
The Hers pen buys three things the LillyDirect vial does not: no needle-and-syringe reconstitution work, direct clinician messaging inside the app, and the branded Hers program structure. Whether those services are worth roughly $1,500 per month more than a vial is the actual decision.
Why Hers is priced where it is
Two forces set the floor.
The first is Lilly's list price. Zepbound in a KwikPen still lists at about $1,086 wholesale to pharmacies; adding a telehealth platform's clinician fees, dispensing, shipping, and margin lands the retail-to-consumer number in the $1,900 range on most branded-pen telehealth programs. Hers is roughly at the market rate for a pen-only branded path.
The second is the end of the compounded shortcut. Through most of 2024, Hims & Hers's headline advantage was compounded tirzepatide at $199 to $299 per month, which used the FDA's shortage-based enforcement discretion to source active pharmaceutical ingredient (API) from bulk. Once the shortage was declared resolved and the courts closed the 503B path, Hims lost the low-cost SKU that made it competitive on tirzepatide, and the only remaining supply chain was brand Zepbound at brand prices. Our compounded tirzepatide legal status guide covers the ruling timeline and what a compliant 503A path looks like today.
Neither force is unique to Hers. Any telehealth brand selling a pen-format Zepbound in 2026 will price near this ceiling. The alternatives below are cheaper because they either bypass the pen (LillyDirect vials) or use the still-legal 503A patient-specific compounding path.
Legal cheaper paths, ranked
The paths below are legal in 2026 for eligible US patients and deliver tirzepatide (or a compounded near-equivalent) rather than a placebo or a knockoff. This is not a Reddit gray-market list. Every option lands you the actual dual GIP and GLP-1 receptor agonist.
1. LillyDirect Self-Pay vials. $299 for 2.5 mg, $399 for 5 mg, $449 flat for 7.5 to 15 mg. Vial-and-syringe format, cash pay only, delivered from a Lilly-partnered pharmacy. Higher-dose tier requires refill within 45 days or price ratchets to standard self-pay ($599, $699, $849, $1,049 respectively). This is the cheapest brand path by a wide margin. Full pricing walkthrough in our Zepbound without-insurance guide.
2. Bodybuilding Health+ compounded semaglutide or tirzepatide. From $139 per month on the 12-month plan. Semaglutide is the primary GLP-1 SKU; tirzepatide is available on a program-eligible basis, subject to the 503A patient-specific rules. Our full Bodybuilding Health+ review covers what actually ships, what the intake looks like, and where the price floors sit.
3. Gala Health compounded microdose. From $149 per month for a tirzepatide microdose formulation with a built-in progress tracker. Microdose formulations are not commercially available at retail, which is why 503A patient-specific compounding of them is compliant with the current framework. See our Gala Health review for the intake and delivery details.
4. TelosRx compounded microdose. From $49 per month on the 12-month plan for a microdosed tirzepatide. Also carries needle-free oral formulations and nasal NAD+ for adjacent stacks.
5. Yucca Health compounded semaglutide. From $206 per month on the 6-month plan. Not tirzepatide, but a serious option if your prescriber is comfortable with semaglutide for the indication. Our Yucca Health review walks through the intake and where the price starts.
For a canonical listing of compounded tirzepatide operators the site has actually vetted, our compounded tirzepatide hub is the current source of truth.
Warning: "Compounded tirzepatide" from an offshore pharmacy or a non-503A operator is not the same product. A 2024 JMIR quality analysis of unlicensed semaglutide products sold online found measured purity of 7.7% to 14.37% against a labeled 99%, with detectable endotoxin in every sample tested. A legitimate 503A path uses a US-licensed pharmacy, a patient-specific prescription from a US-licensed prescriber in your state, and a compounder that meets USP 797 sterile-compounding standards. Cheap is not the same as legal, and legal is not the same as safe.
What tirzepatide actually delivers
Cost is only half the buying decision. What the drug does at the dose is the other half, and here the evidence is unusually clean for the obesity category.
SURMOUNT-1 (Jastreboff et al. 2022, PMID 35658024) enrolled 2,539 adults with obesity (or overweight plus comorbidity) without type 2 diabetes and randomized them to tirzepatide 5 mg, 10 mg, 15 mg, or placebo weekly for 72 weeks. Mean weight loss reached 22.5% at the 15 mg dose, 21.4% at 10 mg, and 16.0% at 5 mg, versus 2.4% on placebo. About 91% of tirzepatide participants lost at least 5% of body weight.
SURMOUNT-5 (Aronne et al. 2025, PMID 40353578) is the head-to-head that made the current price stack legible. In a 751-patient, 72-week open-label randomized trial without diabetes, tirzepatide produced 20.2% mean weight reduction versus 13.7% for semaglutide, with a waist-circumference gap of 18.4 cm versus 13.0 cm. GI-related discontinuation was actually lower on tirzepatide (2.7% vs 5.6%). Our tirzepatide vs semaglutide guide covers the trial in more depth.
SURMOUNT-2 (Garvey et al. 2023, PMID 37385274) confirmed the effect holds in patients with type 2 diabetes: 15.7% weight reduction at 15 mg versus 3.3% on placebo across 72 weeks.
SURMOUNT-4 (Aronne et al. 2023, PMID 38078870) is the one worth reading before you sign a plan longer than the drug will be affordable to you. After a 36-week lead-in on maximum tolerated tirzepatide (mean 20.9% weight loss), participants were randomized 1:1 to continued tirzepatide or placebo. The continued-drug arm lost another 6.7% over 52 weeks. The placebo-switched arm regained about 14% of body weight over the same period. In practical terms, stopping tirzepatide is not a taper to a lower steady state; it is a re-entry to the pre-drug metabolic setpoint.
The takeaway for cost planning: whatever monthly price you accept, expect to sit on it for the medium term, or plan a maintenance path with a prescriber before stopping.
Bottom line: Tirzepatide's clinical case is real. Paying Hers $2,048 per month steady state for a molecule you can get from LillyDirect at $299 to $449 or from a licensed 503A telehealth partner from $139 is a service-tier decision, not a drug-quality decision.
Decision matrix
Pick the row that fits your situation, then follow the linked path.
| Your situation | The path that costs least legally |
|---|---|
| Comfortable with a needle-and-syringe vial, want brand | LillyDirect self-pay vial ($299 to $449) |
| Want a branded pen and can absorb the surcharge | Hers Zepbound ($1,899 + $149/mo membership) |
| Want the pen but not the Hers wrapper | Zepbound retail with GoodRx (about $1,086, per our Zepbound cost guide) |
| Open to compounded tirzepatide from a 503A path | Bodybuilding Health+ (from $139), Gala Health (from $149), TelosRx (from $49 microdose) |
| Open to semaglutide instead | Yucca Health (from $206), Bodybuilding Health+ (from $139) |
| Uninsured, low income, need brand Zepbound at $0 | Lilly Cares Foundation Patient Assistance Program (income-tested) |
If you have already been prescribed tirzepatide through Hers and want to move to a cheaper path, our switching guide covers the mechanics for a within-class dose transition. Continuity of the exact same molecule is the easy case; a different prescriber will typically continue you at the dose Hers had you titrated to, without a washout.
Frequently asked cost questions
Is Hers cheaper than Hims for tirzepatide? No. Hims and Hers are the same company (Hims & Hers Health, Inc.), share the same fulfillment stack, and price Zepbound identically. The women-focused brand is a marketing lane, not a separate pharmacy.
Does insurance cover Hers Zepbound? Hers does not bill insurance for weight-loss medications. If your commercial insurance covers Zepbound with prior authorization, you almost always pay less at a retail pharmacy using the Zepbound Savings Card. Hers is a cash-pay path.
Can I use HSA or FSA for Hers? Usually yes for the medication cost when there is a valid prescription; confirm with your plan administrator. The $149 monthly membership is generally not HSA-eligible on its own.
Do I still get compounded tirzepatide through Hers if I already have a script? Not since mid-2025. Any active Hers-branded compounded tirzepatide subscription was transitioned to brand Zepbound or discontinued. If you are on compounded tirzepatide today, it is being dispensed by a 503A pharmacy under a patient-specific prescription outside the Hers brand.
Is the Hers pen the same tirzepatide as the LillyDirect vial? Yes. Same molecule, same doses (2.5, 5, 7.5, 10, 12.5, 15 mg once weekly), same manufacturer. Format and price differ.
What to do next
If tirzepatide is the answer for you, price the path before you commit. Read our Zepbound without-insurance walkthrough for the LillyDirect and Mounjaro-parity comparisons, our Bodybuilding Health+ review for the compounded telehealth option we currently prefer on cost, and our live GLP-1 cheapest hub for the monthly price watch.
If Hers's wrapper (in-app clinician, refill logistics, program support) is worth the premium to you, the sticker in this article is the honest number for 2026, and the SURMOUNT trial data above is the reason the drug is worth planning around at all.
Research and educational purposes only. This article prices commercial GLP-1 programs and cites published clinical trials. It is not medical advice. GLP-1 medications carry contraindications (personal or family history of medullary thyroid carcinoma, MEN 2, active pancreatitis, severe GI disease, pregnancy) and require prescriber evaluation. Compounded medications are not FDA-approved. Always work with a licensed clinician for prescribing, monitoring, and any change in your treatment.
